Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 16;15(12):3220.
doi: 10.3390/cancers15123220.

Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery

Ilaria Colombo  1 , Katherine Karakasis  2 , Sneha Suku  2 , Amit M Oza  2
Affiliations
Review

Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery

Ilaria Colombo et al. Cancers (Basel). .

Abstract

A deep understanding of the tumor microenvironment and the recognition of tumor-infiltrating lymphocytes as a prognostic factor have resulted in major milestones in immunotherapy that have led to therapeutic advances in treating many cancers. Yet, the translation of this knowledge to clinical success for ovarian cancer remains a challenge. The efficacy of immune checkpoint inhibitors as single agents or combined with chemotherapy has been unsatisfactory, leading to the exploration of alternative combination strategies with targeted agents (e.g., poly-ADP-ribose inhibitors (PARP)and angiogenesis inhibitors) and novel immunotherapy approaches. Among the different histological subtypes, clear cell ovarian cancer has shown a higher sensitivity to immunotherapy. A deeper understanding of the mechanism of immune resistance within the context of ovarian cancer and the identification of predictive biomarkers remain central discovery benchmarks to be realized. This will be critical to successfully define the precision use of immune checkpoint inhibitors for the treatment of ovarian cancer.

Keywords: anti-PD-1/PD-L1; immune checkpoint inhibitors; immune therapy; ovarian cancer; predictive biomarkers; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

I.C.: Speaker, consultancy or advisory role activities for GSK, Astra Zeneca, Novartis, MSD. Travel grants from Tesaro, GSK, Astra Zeneca, Janssen. Research funding (to my institution as PI) from MSD, Bayer, Incyte, AstraZeneca, Vivesto. K.K.: no COI. S.S.: no COI. A.M.O.: PI and Steering Committees with AstraZeneca, GSK and Clovis. Advisory Boards AstraZeneca and Morphosys.

Figures

Figure 1
Figure 1
Immunophenotypes of ovarian cancer and their correlation with sensitivity to immune-checkpoint inhibitors. Created with Biorender.
Figure 2
Figure 2
Combinations of immune checkpoint inhibitors under investigation for the treatment of ovarian cancer.
See this image and copyright information in PMC

References

    1. Cancer Stat Facts: Ovarian Cancer. [(accessed on 10 June 2023)]; Available online: https://seer.cancer.gov/statfacts/html/ovary.html.
    1. Colombo N., Sessa C., du Bois A., Ledermann J., McCluggage W.G., McNeish I., Morice P., Pignata S., Ray-Coquard I., Vergote I., et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann. Oncol. 2019;30:672–705. doi: 10.1093/annonc/mdz062. - DOI - PubMed
    1. Tew W.P., Lacchetti C., Ellis A., Maxian K., Banerjee S., Bookman M., Jones M.B., Lee J.-M., Lheureux S., Liu J.F., et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J. Clin. Oncol. 2020;38:3468–3493. doi: 10.1200/JCO.20.01924. - DOI - PMC - PubMed
    1. Tew W.P., Lacchetti C., Kohn E.C., PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update. J. Clin. Oncol. 2022;40:3878–3881. doi: 10.1200/JCO.22.01934. - DOI - PubMed
    1. Caruso G., Tomao F., Parma G., Lapresa M., Multinu F., Palaia I., Aletti G., Colombo N. Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: Lessons learned and future directions. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 2023;33:431–443. doi: 10.1136/ijgc-2022-004149. - DOI - PubMed